FI
EIGR

Fosun International’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Fosun International’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,840
Closed -$1.55M – 299
2019
Q2 		$1.55M Hold
4,840
– – 0.1% 128
2019
Q1 		$1.97M Sell
4,840
-1,220
-20% -$490K 0.13% 105
2018
Q4 		$1.69M Buy
+6,060
New +$1.96M 0.1% 97

Other funds holding EIGR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Fosun International's EIGR Position: Q3 2019 in Review

Fosun International sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2019, closing a stake of 4,840 shares — an estimated $1.55M sold.

Fosun International first reported a position in EIGR in Q4 2018 and held it in 3 quarters. The position peaked at $1.97M in Q1 2019. 84 funds tracked by Wall St. Rank hold EIGR as of Q3 2019.

  • Fosun International reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 4,840 Eiger BioPharmaceuticals, Inc. shares in Q3 2019, an estimated $1.55M.
  • Fosun International first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
  • Fosun International's Eiger BioPharmaceuticals, Inc. position peaked at $1.97M in Q1 2019.
  • 84 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.